Literature DB >> 8849754

Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

M C Weinstein1, J E Siegel, M R Gold, M S Kamlet, L B Russell.   

Abstract

OBJECTIVE: To develop consensus-based recommendations for the conduct of cost-effectiveness analysis (CEA). This article, the second in a 3-part series, describes the basis for recommendations constituting the reference case analysis, the set of practices developed to guide CEAs that inform societal resource allocation decisions, and the content of these recommendations. PARTICIPANTS: The Panel on Cost-Effectiveness in Health and Medicine, a nonfederal panel with expertise in CEA, clinical medicine, ethics, and health outcomes measurement, was convened by the US Public Health Service (PHS). EVIDENCE: The panel reviewed the theoretical foundations of CEA, current practices, and alternative methods used in analyses. Recommendations were developed on the basis of theory where possible, but tempered by ethical and pragmatic considerations, as well as the needs of users. CONSENSUS PROCESS: The panel developed recommendations through 2 1/2 years of discussions. Comments on preliminary drafts prepared by panel working groups were solicited from federal government methodologists, health agency officials, and academic methodologists.
CONCLUSIONS: The panel's methodological recommendations address (1) components belonging in the numerator and denominator of a cost-effectiveness (C/E) ratio; (2) measuring resource use in the numerator of a C/E ratio; (3) valuing health consequences in the denominator of a C/E ratio; (4) estimating effectiveness of interventions; (5) incorporating time preference and discounting; and (6) handling uncertainty. Recommendations are subject to the ¿rule of reason,¿ balancing the burden engendered by a practice with its importance to a study. If researchers follow a standard set of methods in CEA, the quality and comparability of studies, and their ultimate utility, can be much improved.

Entities:  

Mesh:

Year:  1996        PMID: 8849754

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  635 in total

Review 1.  Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?

Authors:  C Bombardier; A Maetzel
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Cost utility analysis of radiographic screening for an orbital foreign body before MR imaging.

Authors:  D J Seidenwurm; C H McDonnell; N Raghavan; J Breslau
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

Review 3.  Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.

Authors:  A O'Hagan; J W Stevens; J Montmartin
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

4.  Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?

Authors:  Andreas Laupacis
Journal:  CMAJ       Date:  2002-01-08       Impact factor: 8.262

Review 5.  Criteria for evaluating evidence on public health interventions.

Authors:  L Rychetnik; M Frommer; P Hawe; A Shiell
Journal:  J Epidemiol Community Health       Date:  2002-02       Impact factor: 3.710

6.  Assessing the cost-effectiveness of pharmacogenomics.

Authors:  D L Veenstra; M K Higashi; K A Phillips
Journal:  AAPS PharmSci       Date:  2000

7.  Economic analyses and clinical practice guidelines: why not a match made in heaven?

Authors:  Scott D Ramsey
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

8.  Economic analysis of randomized, controlled trials.

Authors:  G H Lyman
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 9.  AIDS policy modeling for the 21st century: an overview of key issues.

Authors:  M S Rauner; M L Brandeau
Journal:  Health Care Manag Sci       Date:  2001-09

10.  Newborn mass screening versus selective investigation: benefits and costs.

Authors:  R J Pollitt
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.